Loss of arylformamidase with reduced thymidine kinase expression leads to impaired glucose tolerance

Biology Open

Volumn 4, Issue 11, 2015, Pages 1367-1375

  Hugill, Alison J ^a   Stewart, Michelle E ^b   Yon, Marianne A ^a   Probert, Fay ^b,c   Cox, I Jane ^c   Hough, Tertius A ^b   Scudamore, Cheryl L ^b   Bentley, Liz ^a   Wall, Gary ^a   Wells, Sara E ^b   Cox, Roger D ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Medical Research Council Harwell Institute   (United Kingdom)

^c INSTITUTE OF HEPATOLOGY   (United Kingdom)

Author keywords

Arylformamidase; Diabetes; Insulin secretion; Kynurenine; Tryptophan

Indexed keywords

ARYLFORMAMIDASE; KYNURENIC ACID; THYMIDINE KINASE; XANTHURENIC ACID;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PROTEIN DEPLETION; PROTEIN EXPRESSION;

EID: 84982787188     PISSN: None     EISSN: 20466390     Source Type: Journal    
DOI: 10.1242/bio.013342     Document Type: Article

References (26)

1. Bradley, A., Anastassiadis, K., Ayadi, A., Battey, J. F., Bell, C., Birling, M.-C., Bottomley, J., Brown, S. D., Burger, A., Bult, C. J. et al. (2012). The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm. Genome 23, 580-586.
2. Dobrovolsky, V. N., Bucci, T., Heflich, R. H., Desjardins, J. and Richardson, F. C. (2003). Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Mol. Genet. Metab. 78, 1-10.
3. Dobrovolsky, V. N., Bowyer, J. F., Pabarcus, M. K., Heflich, R. H., Williams, L. D., Doerge, D. R., Arvidsson, B., Bergquist, J. and Casida, J. E. (2005). Effect of arylformamidase (kynurenine formamidase) gene inactivation in mice on enzymatic activity, kynurenine pathway metabolites and phenotype. Biochim. Biophys. Acta 1724, 163-172.
4. Hattori, M., Kotake, Y. and Kotake, Y. (1984). Studies on the urinary excretion of xanthurenic acid in diabetics. Acta Vitaminol. Enzymol. 6, 221-228.
5. Ikeda, S. and Kotake, Y. (1986). Urinary-excretion of xanthurenic acid and zinc in diabetes .3. Occurrence of Xanthurenic acid-Zn-2+ complex in urine of diabeticpatients and of experimentally-diabetic rats. Ital. J. Biochem. 35, 232-241.
6. Kotake, Y., Ueda, T., Mori, T., Igaki, S. and Hattori, M. (1975). Abnormal tryptophan-metabolism and experimental diabetes by Xanthurenic acid (Xa). Acta Vitaminol. Enzymol. 29, 236-239.
7. Kozak, R., Campbell, B. M., Strick, C. A., Horner, W., Hoffmann, W. E., Kiss, T., Chapin, D. S., McGinnis, D., Abbott, A. L., Roberts, B. M. et al. (2014). Reduction of brain kynurenic acid improves cognitive function. J. Neurosci. 34, 10592-10602.
8. Lemieux, G. A., Cunningham, K. A., Lin, L., Mayer, F., Werb, Z. and Ashrafi, K. (2015). Kynurenic acid is a nutritional cue that enables behavioral plasticity. Cell 160, 119-131.
9. McGaha, T. L., Huang, L., Lemos, H., Metz, R., Mautino, M., Prendergast, G. C. and Mellor, A. L. (2012). Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol. Rev. 249, 135-157.
10. Munipally, P. K., Agraharm, S. G., Valavala, V. K., Gundae, S. and Turlapati, N. R. (2011). Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch. Physiol. Biochem. 117, 254-258.
11. Noto, Y. and Okamoto, H. (1978). Inhibition by kynurenine metabolites of proinsulin synthesis in isolated pancreatic-islets. Acta Diabetol. Latina 15, 273-282.
12. Okamoto, H. (1975). Effect of quinaldic acid and its relatives on insulin-release from isolated Langerhans islets. Acta Vitaminol. Enzymol. 29, 227-231.
13. Oxenkrug, G. (2013). Insulin resistance and dysregulation of tryptophankynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol. Neurobiol. 48, 294-301.
14. Oxenkrug, G. F., Turski, W. A., Zgrajka, W., Weinstock, J. V. and Summergrad, P. (2013). Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat. Res. Treat. 2013, 149247.
15. Pabarcus, M. K. and Casida, J. E. (2002). Kynurenine formamidase: determination of primary structure and modeling-based prediction of tertiary structure and catalytic triad. Biochim. Biophys. Acta 1596, 201-211.
16. Pabarcus, M. K. and Casida, J. E. (2005). Cloning, expression, and catalytic triad of recombinant arylformamidase. Protein Expr. Purif. 44, 39-44.
17. Patterson, A. D., Bonzo, J. A., Li, F., Krausz, K. W., Eichler, G. S., Aslam, S., Tigno, X., Weinstein, J. N., Hansen, B. C., Idle, J. R. et al. (2011). Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J. Biol. Chem. 286, 19511-19522.
18. Pettitt, S. J., Liang, Q., Rairdan, X. Y., Moran, J. L., Prosser, H. M., Beier, D. R., Lloyd, K. C., Bradley, A. and Skarnes, W. C. (2009). Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat. Methods 6, 493-495.
19. Rogers, K. S. and Evangelista, S. J. (1985). 3-Hydroxykynurenine, 3-hydroxyanthranilic acid, and o-aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets. Exp. Biol. Med. 178, 275-278.
20. Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D'Angelo, C., Zelante, T., Vacca, C., Bistoni, F., Fioretti, M. C., Grohmann, U. et al. (2008). Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451, 211-215.
21. Shimomura, K., Galvanovskis, J., Goldsworthy, M., Hugill, A., Kaizak, S., Lee, A., Meadows, N., Quwailid, M. M., Rydstrom, J., Teboul, L. et al. (2009). Insulin secretion from beta-cells is affected by deletion of nicotinamide nucleotide transhydrogenase. Methods Enzymol. 457, 451-480.
22. Skarnes, W. C., Rosen, B., West, A. P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A. O., Thomas, M., Harrow, J., Cox, T. et al. (2011). A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337-342.
23. Stone, T. W. and Darlington, L. G. (2002). Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1, 609-620.
24. Stone, T. W. and Darlington, L. G. (2013). The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br. J. Pharmacol. 169, 1211-1227.
25. van der Kloet, F. M., Tempels, F. W. A., Ismail, N., van der Heijden, R., Kasper, P. T., Rojas-Cherto, M., van Doorn, R., Spijksma, G., Koek, M., van der Greef, J. et al. (2012). Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 8, 109-119.
26. Wu, W., Nicolazzo, J. A., Wen, L., Chung, R., Stankovic, R., Bao, S. S., Lim, C. K., Brew, B. J., Cullen, K. M. and Guillemin, G. J. (2013). Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS ONE 8, e59749.